Hospitals Cannot Mandate In-House Pharmacy Purchases, Says Maharashtra FDA

The Maharashtra Food and Drug Administration (FDA) has stepped in to protect patient choice after receiving complaints that some hospitals were allegedly compelling patients to purchase medicines from their in-house pharmacies or from specific chemist shops. The move has brought renewed attention to broader concerns around patient rights , healthcare affordability, and consumer protection in India's medical sector, where access to medicines and transparency in pricing remain key challenges.

Addressing a press conference, FDA Commissioner Tukaram Mundhe clarified that no hospital has the legal authority to force patients to buy medicines from a particular pharmacy. He said the regulator had received several complaints regarding such practices and has issued directions to prevent them. The clarification reinforces a basic principle of healthcare consumer rights: patients are free to purchase prescribed medicines from any licensed pharmacy of their choice.

The issue, however, extends beyond direct coercion. Many multispeciality hospitals operate their own pharmacies and stock specific brands of medicines, implants, and specialty drugs that may not be readily available in nearby retail outlets. As a result, patients often find it difficult to source the exact medicines prescribed by doctors outside the hospital premises. In many cases, doctors prescribe branded medicines instead of generic drug names, limiting the patient's ability to compare prices or choose equivalent alternatives available in the market.

The debate also highlights the importance of India's Charter of Patients' Rights , prepared by the National Human Rights Commission (NHRC) and circulated by the Ministry of Health and Family Welfare . The framework recognizes a patient's right to information, informed consent, access to medical records, transparency in billing, privacy, non-discriminatory treatment, and the freedom to seek medicines and diagnostic services from providers of their choice.

Healthcare experts argue that the current system often creates an information imbalance between doctors and patients. Most patients lack the technical knowledge needed to evaluate prescriptions or identify lower-cost alternatives, making them vulnerable to higher medicine costs and limited choices. Since medicines account for a significant share of out-of-pocket healthcare expenditure in India, concerns about pharmacy practices have direct financial implications for households.

The problem is often more pronounced in rural and semi-urban areas, where local doctors may routinely direct patients to a single pharmacy. Limited competition, low consumer awareness, and a shortage of alternative suppliers can effectively restrict patient choice even in the absence of formal mandates. Consumer rights advocates have repeatedly called for stronger monitoring of referral patterns and greater transparency in prescribing practices.

The Maharashtra FDA's intervention has also revived discussions on possible reforms. Experts have suggested mandatory generic prescribing , improved price transparency, regulation of excessive pharmacy markups, and wider adoption of digital prescription systems that allow patients to compare medicine prices and identify generic alternatives. There have also been calls to strengthen the network of government-supported generic medicine stores under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana .

While some observers have proposed fixed discount requirements for hospital pharmacies, policy experts believe the more sustainable solution lies in increasing competition, promoting generic medicines, and ensuring patients have access to clear information. For regulators, the challenge is not only preventing hospitals from directing patients to specific pharmacies but also ensuring that patients can exercise their rights in a meaningful and informed manner. The FDA's latest directive serves as a reminder that healthcare decisions should be guided by medical necessity, transparency, and patient choice , rather than commercial considerations.